NRx Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business UpdatePRNewsWire • 05/16/23
NRx Pharmaceuticals Reschedules First Quarter 2023 Financial Results Conference CallPRNewsWire • 05/10/23
NRx Pharmaceuticals to Report First Quarter 2023 Financial Results on May 11, 2023PRNewsWire • 04/27/23
NRx Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Business UpdatePRNewsWire • 03/30/23
NRx Pharmaceuticals Announces Positive Recommendation to Continue Enrollment in the Ongoing Trial of NRX-101 in Patients with Suicidal Treatment-Resistant Bipolar DepressionPRNewsWire • 03/27/23
NRx Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on March 30, 2023PRNewsWire • 03/17/23
NRx Pharmaceuticals Builds on Its Intellectual Property Foundation for Neuropsychiatric Conditions - Adds New U.S. Patent to PortfolioPRNewsWire • 02/22/23
NRx Pharmaceuticals Reports Minutes of Recent U.S. Food and Drug Administration (FDA) Meeting on the Development of NRX-101 to Treat Severe Bipolar Depression in Patients with SuicidalityPRNewsWire • 02/13/23
NRx Pharmaceuticals Reports Recommendations of Data Safety Monitoring Board for Trial of NRX-101 in Patients with Severe Bipolar Depression and Subacute Suicidal Ideation or BehaviorPRNewsWire • 02/02/23
NRx Pharmaceuticals Provides Progress Update on Interactions with the FDA regarding Path to NDA Submission for NRX-101PRNewsWire • 01/19/23
NRx Pharmaceuticals to Present Scientific Update at the 6th Annual Sachs Associates Neuroscience Innovation Forum in Conjunction with the 2023 J.P. Morgan Healthcare ConferencePRNewsWire • 01/05/23
NRx Pharmaceuticals Initiates Phase 3 Trial Treating Patients with Bipolar Depression with Acute Suicidality - First Clinical Site ContractedPRNewsWire • 01/03/23
Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Close of Definitive Settlement AgreementsAccesswire • 12/20/22
NRx Pharmaceuticals Announces the Appointment of Carrie M. Carretta, PhD, APN-BC, AHN-BC, PMHNP, Senior Vice President of Clinical Development and Medical AffairsPRNewsWire • 12/05/22
NRx Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business UpdatePRNewsWire • 11/14/22
NRx Pharmaceuticals Produces First Phase 3-stage NRX-101 Drug Made Using Commercial ProcessPRNewsWire • 11/09/22